View : 417 Download: 0
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
- Title
- Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
- Authors
- Lee, Yun-Gyoo; Chang, Hyun; Keam, Bhumsuk; Chun, Sang Hoon; Park, Jihyun; Park, Keon Uk; Shin, Seong Hoon; An, Ho Jung; Lee, Kyoung Eun; Lee, Keun-Wook; Kim, Hye Ryun; Kim, Sung-Bae; Ahn, Myung-Ju; Hwang, In Gyu
- Ewha Authors
- 이경은
- SCOPUS Author ID
- 이경은
![scopus](/images/layout/icon2.png)
![scopus](/images/layout/icon2.png)
- Issue Date
- 2021
- Journal Title
- CANCER RESEARCH AND TREATMENT
- ISSN
- 1598-2998
2005-9256
- Citation
- CANCER RESEARCH AND TREATMENT vol. 53, no. 3, pp. 671 - 677
- Keywords
- Head and neck neoplasms; Biomarkers; Immune check point; Platinum refractory; Sum of target lesions
- Publisher
- KOREAN CANCER ASSOCIATION
- Indexed
- SCIE; SCOPUS; KCI
![WOS](/images/layout/wos.gif)
- Document Type
- Article
- Abstract
- Purpose This study was conducted to determine the effectiveness of immune checkpoint inhibitors (ICIs) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum-containing chemotherapy. We also identified clinical biomarkers which may be predictive of patient prognosis. Materials and Methods We analyzed 125 patients with R/M HNSCC who received ICIs, retrospectively. Overall response rate (ORR) was the primary study outcome. Overall survival (OS) and progression-free survival (PFS) were the secondary study outcomes. Results The patients received anti & ndash;programmed cell death protein-1 (PD-1) (n=73, 58%), anti & ndash;programmed death-ligand 1 (PD-L1) (n=24, 19%), or a combination of anti & ndash;PD-1/PD-L1 and anti & ndash;cytotoxic T-lymphocyte antigen 4 (n=28, 22%). The median age was 57 years (range, 37 to 87). The location of the primary tumor was in the oral cavity in 28% of the cases, followed by oropharynx (27%), hypopharynx (20%), and larynx (12%). The ORR was 15% (19/125). With 12.3 months of median follow-up, median PFS was 2.7 months. Median OS was 10.8 months. A neutrophil-to-lymphocyte ratio (NLR) > 4 was significantly associated with poor response to ICIs (odds ratio, 0.30; p=0.022). A sum of the target lesions > 40 mm (hazard ratio [HR], 1.53; p=0.046] and a NLR > 4 (HR, 1.75; p=0.009) were considered to be predictive markers of short PFS. A poor performance status (HR, 4.79; p < 0.001), a sum of target lesions > 40 mm (HR, 1.93; p=0.025), and an NLR > 4 (HR, 3.36; p < 0.001) were the significant predictors for poor survival. Conclusion ICIs exhibited favorable antitumor activity in R/M HNSCC. Clinically, our findings can be used to recognize patients benefit from receiving ICI.
- DOI
- 10.4143/crt.2020.824
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML